Shinpoong Pharmaceutical Co.,Ltd (KRX: 019170)

Market Cap	571.11B
Revenue (ttm)	208.78B
Net Income (ttm)	-41.63B
Shares Out	51.26M
EPS (ttm)	-812.13
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,272
Open	10,550
Previous Close	10,700
Day's Range	10,550 - 11,100
52-Week Range	10,100 - 19,850
Beta	0.81
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 14, 2024

About Shinpoong Pharmaceutical Co.,Ltd

Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial drug; and drugs for treating hypercholesterolemia, knee osteoarthritis and shoulder periarthritis, and surgical adhesion barrier; prescription drugs; woun...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1962
• Employees: 828
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 019170

Financial Performance

In 2023, Shinpoong Pharmaceutical Co.,Ltd's revenue was 200.23 billion, a decrease of -4.33% compared to the previous year's 209.29 billion. Losses were -55.13 billion, 55.8% more than in 2022.